2025 CASH丨Dr. Suning Chen: Focusing on Annual Advances in AML—Integrating Innovation for a Better Future

2025 CASH丨Dr. Suning Chen: Focusing on Annual Advances in AML—Integrating Innovation for a Better Future

The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, featuring the theme of “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” The event invited top hematology experts from China and abroad to discuss the latest advancements and future trends in the field.
2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines

2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines

The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” Top hematology experts from China and abroad were invited to discuss the latest advancements and future trends in hematology.
2025 CASH丨Another Milestone! Dr. Jing Pan’s Team Recognized in the Top 10 Hematology Research Advancements of 2024

2025 CASH丨Another Milestone! Dr. Jing Pan’s Team Recognized in the Top 10 Hematology Research Advancements of 2024

From January 3–5, 2025, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) was held in Tianjin under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” As a key highlight of the conference, the Top 10 Hematology Research Advancements of 2024 were announced during the closing ceremony, recognizing significant scientific achievements in the field of hematology over the past year.
Annual Review | Prof. Jun Ma: 2024 Updates on Guidelines and Advances in Acute Lymphoblastic Leukemia (ALL)

Annual Review | Prof. Jun Ma: 2024 Updates on Guidelines and Advances in Acute Lymphoblastic Leukemia (ALL)

In recent years, the field of hematologic oncology has witnessed remarkable breakthroughs, with acute lymphoblastic leukemia (ALL) emerging as a focal point of progress. Chinese researchers have made significant contributions, driving milestone advancements in both research and clinical practice. To usher in the new year, Hematology Frontier invited Professor Jun Ma from the Harbin Institute of Hematology and Oncology to provide an in-depth review of the key developments in ALL during 2024. This comprehensive analysis aims to guide clinical practice and inspire future research.
Annual Review | Prof. Shuhua Yi: Highlights of 2024 Advances in Mantle Cell Lymphoma

Annual Review | Prof. Shuhua Yi: Highlights of 2024 Advances in Mantle Cell Lymphoma

In recent years, the field of hematologic oncology has experienced remarkable breakthroughs, with significant advancements in mantle cell lymphoma (MCL). Chinese researchers have increasingly contributed to this progress, playing a pivotal role in driving academic development and clinical practice in the field. As we step into the new year, Hematology Frontier invited Professor Shuhua Yi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to review the major events and breakthroughs in MCL during 2024. This comprehensive summary aims to provide valuable insights for clinical practice and future research directions.
Annual Review | Dr. Liangyou Gu: Advances in Perioperative Treatment of Renal Cancer in 2024

Annual Review | Dr. Liangyou Gu: Advances in Perioperative Treatment of Renal Cancer in 2024

Renal cancer is a common malignancy of the urinary system. For localized and locally advanced renal cancer without distant or extraregional lymph node metastases, surgical removal of the tumor or the affected kidney remains the primary treatment. Recent advances in targeted therapy and immunotherapy have expanded the options for perioperative treatment of renal cancer. In 2024, this field saw significant breakthroughs, and Dr. Liangyou Gu from the Chinese PLA General Hospital shared the latest research developments.